29 septiembre 2014
The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/7MAc4seGrvE/140929090344.htm
